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Type I interferon (IFN) induces antiviral responses through the activation of the ISGF3 transcription factor complex that
contains the subunit proteins STAT1, STAT2, and p48/ISGF3g/IRF9. The ability of some human paramyxoviruses to overcome
IFN actions by specific proteolysis of STAT proteins has been examined. Infection of cells with type 2, but not type 1 or type
3 human parainfluenza virus (HPIV) leads to a loss of cellular STAT2 protein. Expression of a single HPIV2 protein derived
from the V open reading frame blocks IFN-dependent transcriptional responses in the absence of other viral proteins. The
loss of IFN response is due to V-protein-induced proteolytic degradation of STAT2. Expression of HPIV2 V causes the
normally stable STAT2 protein to be rapidly degraded, and this proteolytic activity can be partially alleviated by proteasome
inhibition. No V-protein-specific effects on STAT2 mRNA levels were observed. The results indicate that the V protein of
HPIV2 is sufficient to recognize and target a specific cellular transcription factor for destruction by cellular machinery.
© 2001 Academic PressKey Words: STAT; ISGF3; interferon; paramyxovirus; V protein; HPIV2; proteolysis.
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Cellular response to virus infection involves both in-
nate and adaptive host immune functions. Interferons
(IFNs) have long been recognized as the mediators of
innate antiviral responses. Type I IFNs, IFNa and IFNb,
are the principal antiviral cytokines produced by mam-
malian cells and function directly on target cells by
blocking viral replication (Isaacs and Lindemann, 1957;
reviewed in Goodbourn et al., 2000).
IFN-dependent interference with viral infection relies
on a failure of viral mRNA translation or of viral nucleic
acid replication, but the molecular basis for the antiviral
state is still not completely understood. It is known that
the establishment of the cellular antiviral state requires
mRNA and protein synthesis following IFNa treatment.
FNa/b-induced proteins that contribute to the antiviral
tate are known and these proteins are often the target
f virus IFN antagonism (reviewed in Goodbourn et al.,
000). Well-studied examples include activation of such
roteins as the double-stranded RNA-dependent protein
inase (protein kinase R), the double-stranded RNA-
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ystem, and the IFN-induced Mx proteins. The effects of
FNa/b in causing the overall antiviral state depend on
he synthesis of one or more of these proteins and
dditional other pathways that have been uncovered in
tudies of mice deficient in all three of these antiviral
ffectors (Zhou et al., 1999).
Analysis of the promoters of many IFNa/b-stimulated
enes revealed a DNA response element specific for
ype I IFN induction, the IFN stimulated response ele-
ent (ISRE; reviewed in Darnell, 1997; Horvath, 2000).
SGF3 was identified as the protein factor that binds to
his response element and was found to contain three
roteins from two transcription factor families. Two sub-
nits are members of the signal transducer and activator
f transcription (STAT) family. The IFNa/b-activated factor
(ISGF3) contains a heterodimer of STAT1 and STAT2
complexed with a third protein, a member of the inter-
feron regulatory factor family referred to as ISGF3g, p48,
r IRF9. The IRF9 protein is an essential component of
SGF3 that confers DNA binding specificity to the ISGF3
omplex (Levy et al., 1989) and provides specific protein
inding recruitment sites for the STAT1 and STAT2 pro-
eins (Horvath et al., 1996; Lau et al., 2000; Martinez-
Moczygemba et al., 1997).
STAT1 and STAT2 are required for ISGF3 signaling, but
are not redundant in this pathway. STAT1 protein is a
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231HPIV2 V PROTEIN TARGETS STAT2component of both the Type I IFN-induced ISGF3 com-
plex and the Type II IFN-induced GAF complex and
consequently cells lacking STAT1 have no antiviral re-
sponse to either IFN (Horvath and Darnell, 1996). Full
IFNa/b antiviral activity requires only that STAT1 be
phosphorylated on tyrosine, but either STAT1a or STAT1b
(a form of STAT1a lacking the 38-amino-acid transcrip-
ional activation domain) will suffice (Horvath and Dar-
ell, 1996). These results indicate that while STAT1 is
ndispensable for ISGF3-induced antiviral effects, STAT2
lays a crucial role as the transcription activating protein
omponent in ISGF3. STAT2 is clearly essential for IFN
esponses and ISGF3 function, as deficiencies in STAT2
an disrupt ISGF3 signaling and lead to decreased ex-
ression of antiviral genes (Leung et al., 1995; Qureshi et
l., 1996).
As the IFNa/b system represents an early and crucial
tep in anti-viral immunity, it is not surprising that many
iruses have evolved strategies to impede the actions of
his cytokine (reviewed in Goodbourn et al., 2000). The
bility of a virus to antagonize the IFNa/b pathway can
have dramatic consequences for the success of infec-
tion, as illustrated in several cases where the IFN antag-
onizing genes were deleted to form attenuated viruses
(for example, Bergmann et al., 2000; Kitajewski et al.,
1986). The virulence of a specific strain can be correlated
with its susceptibility to the antiviral effects of IFNa/b,
and evolution of strategies to enhance IFNa/b resistance
are expected to lead to highly infectious viruses and/or
persistent infections. A wide variety of viruses fight the
IFNa/b system at a variety of steps, in many cases at an
early point upstream of gene activation, antagonizing
both IFN responses and IFN production (Bergmann et al.,
2000; Kitajewski et al., 1986; Talon et al., 2000).
Negative-strand RNA viruses of the family Paramyxo-
iridae have evolved specific proteins that directly sup-
ress IFN signaling by lowering the concentration of
ellular STAT proteins. For example, Sendai virus has
een demonstrated recently to block IFN responses
hrough the actions of its C proteins (Garcin et al., 1999).
Expression of this single viral protein is sufficient to
cause a loss of STAT protein inducibility at the transcrip-
tional level. The mechanism of STAT1 transcriptional
suppression is unknown, but is suspected to involve
interaction of C proteins with cellular factors (Garcin et
al., 1999, 2000). A second paramyxovirus, SV5, was dem-
onstrated recently to evade IFN antiviral responses by
specifically targeting the transcription factor STAT1 for
proteolytic degradation (Didcock et al., 1999). This de-
struction of STAT1 was found to be mediated by the sole
expression of a single virus-encoded protein derived
from the V open reading frame (Didcock et al., 1999).
Subsequent analysis indicated that while most
paramyxoviruses can block IFN signaling, the ability to
degrade STAT1 was a unique property of SV5 (Young et
al., 2000). Somewhat surprisingly, it was also foundthat in cells infected with human parainfluenza virus 2
(HPIV2), STAT1 was not degraded, but rather a loss of
STAT2 was observed (Young et al., 2000). The mecha-
nism of STAT2 degradation or the viral gene responsible
for catalyzing its destruction was not investigated in this
study.
As a first step in understanding the specificity of STAT
protein degradation by paramyxoviruses and defining the
cellular machinery involved in this process, we investi-
gated the ability of the HPIV2 V protein to mediate loss of
STAT2 protein in the absence of other viral proteins. Our
results corroborate the finding that infection of cultured
cells with HPIV2, but not with HPIV1 or HPIV3, causes a
dramatic reduction of STAT2 protein steady-state levels.
Moreover, we demonstrate that the expression of HPIV2
V protein from a cDNA clone is sufficient to abolish IFN
responsive transcriptional activity. Our data illustrate that
expression of the HPIV2 V protein in cultured cells did
not influence STAT2 mRNA abundance, but instead was
found to reduce steady-state STAT2 protein levels by
increasing its degradation rate, leading to uncharacter-
istic STAT2 instability. Interestingly, this proteolysis is
only partially alleviated by proteasome inhibitors, sug-
gesting that alternatives to the ubiquitin–proteasome
degradation system may be responsible for the V protein
actions.
RESULTS
Effects of HPIV infection on steady state STAT1 and
STAT2 protein levels
To examine the effects of human parainfluenza viruses
on steady-state levels of STAT proteins, cultured cells
were infected with human parainfluenza viruses (HPIV)
1–3. At 9 h postinfection, cells were lysed in whole cell
extract buffer and subjected to SDS–PAGE and immuno-
blotting with antisera for STAT1 and STAT2. Despite a
small reduction in STAT1 in HPIV1-infected cells, only
minor differences in STAT1 levels were observed. STAT2
was found to be stable during infection with HPIV1 and
HPIV3. In fact, a stronger STAT2 signal was detected
following infection with HPIV1 and HPIV3 compared to
uninfected cells, possibly indicating induction of STAT2
expression by these viruses. In contrast, HPIV2 infection
caused a nearly complete loss of STAT2 protein (Fig. 1).
This result indicates that HPIV2 infection induces a re-
duction in the STAT2 expression level in agreement with
the prior data (Young et al., 2000).
Expression of HPIV2 V protein from
transfected cDNA
The degradation of STAT1 as a result of SV5 infection
was found to be mediated by the V protein. The HPIV2
virus codes for a V protein that is 44% identical in amino
acid sequence to the SV5 V protein. This high degree of
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232 PARISIEN ET AL.identity is spread throughout the length of the protein
with especially high conservation in the C-terminal cys-
teine-rich domain. The extensive homology between the
two proteins suggested that the HPIV2 V protein might
be involved in the observed loss of STAT2. As a first step
toward understanding the molecular events involved in
virus-induced reduction of STAT protein stability, the role
of HPIV2 V in catalyzing the loss of STAT2 was investi-
gated.
For mammalian cell expression, the V protein cDNA
was subcloned into the mammalian expression vector,
pRcCMV, under control of a constitutively active cyto-
megalovirus promoter. To verify the integrity of our con-
struct, expression of the V protein was tested in human
embryonic kidney 293 T cells. Duplicate plates of cells
were transfected with control vector or HPIV2 expression
vector and extracts were prepared 48 h later. The ex-
tracts were separated by SDS–PAGE and transferred to
nitrocellulose filters. Probing these blots with an anti-
serum generated against HPIV2-infected cells resulted
in recognition of a novel band in the V-transfected cells
migrating at the position of approximately 27–30 kDa on
the SDS gel, in general agreement with the theoretical
molecular weight of the HPIV2 V protein calculated from
the amino acid sequence (24,150 kDa; Fig. 2A) (Ohgimoto
et al., 1990).
Expression of HPIV2 V protein leads to loss of
cellular STAT2 protein
To determine the effect of HPIV2 V protein expression
on steady-state levels of STAT2 protein, cells were trans-
fected with pRcCMV vector or pRcCMV HPIV2 V and
extracts prepared at 48 h posttransfection following a 6-h
treatment with or without IFNa. Samples were separated
by SDS–PAGE, transferred to nitrocellulose, and probed
with a STAT2-specific antiserum. STAT2 levels were con-
sistently reduced to ;30–50% upon HPIV2 V protein
expression compared with controls and IFN treatment
did not alter this effect of V protein expression (Fig. 2B).
A similar reduction of STAT2 protein levels was observed
in all human cell lines tested (including Hela, 2fTGH, and
FIG. 1. STAT2 protein level decreases during HPIV2 infection. CV1
cells were infected with human parainfluenza viruses 1–3 at the indi-
cated multiplicity of infection (m.o.i.) for 9 h. C, control uninfected cells.
Whole cell lysates (50 mg protein) were separated by SDS–PAGE and
ransferred to nitrocellulose filters for immunoblotting with antisera
pecific for STAT1 or STAT2.U3A; data not shown), and effects were most apparent in tthe efficiently transfected 293T cell line shown, where
cotransfected GFP expression plasmid was found to be
expressed in nearly all cells prior to lysate preparation.
Stripping and reprobing with a STAT1-specific antiserum
demonstrates no loss of STAT1 protein, indicating that
the effect of HPIV2 V is specific for STAT2. This result
indicates that the V protein of HPIV2 does alter the
accumulation of STAT2 protein, but in the transfection
system the loss of STAT2 was not as complete as that
observed upon HPIV2 virus infection. The difference be-
tween the two systems might reflect fundamental biolog-
ical differences inherent in expression of the V protein
from a transfected CMV promoter-driven expression vec-
tor versus that from a native HPIV2 promoter in the
context of virus infection. One explanation to account for
this effect is that in the transfected cells, newly synthe-
sized STAT2 might replenish the steady-state pool of
protein.
Expression of HPIV2 V protein causes a loss of IFN
responsive ISGF3 activity
To determine the effect of V protein expression and
subsequent loss of STAT2 protein on type I IFN signaling,
a luciferase reporter gene assay was used to measure
ISRE-dependent transcriptional activity. Cells were trans-
fected with a reporter plasmid containing five copies of
the ISG-54 ISRE element upstream of a luciferase re-
porter gene, a LacZ control plasmid, and either pRcCMV
vector or pRcCMV HPIV2 V. Cells were treated with IFN
for 6 h prior to lysis and luciferase assay. As a control, in
place of the HPIV2 V plasmid, an SV5 V expression
plasmid was expressed in alternate plates. The reporter
gene has a low basal activity in the absence of IFN
FIG. 2. Expression of HPIV2 V ORF reduces the abundance of cellular
STAT2 protein. A. Expression of HPIV2 V protein from cDNA. Duplicate
plates of 293T cells were transfected with pRcCMV vector or pRcCMV-
HPIV2 as indicated, and cell extracts were prepared 48 h later and
subjected to immunoblotting with total HPIV2 antiserum. The positions
of the V protein and a 32-kDa prestained molecular weight marker are
indicated. B. Expression of HPIV2 V protein reduces the steady-state
level of STAT2. Transfected cells were treated with or without IFN-a at
2 h posttransfection, and whole cells extracts were prepared 6 h later.
teady-state STAT1 and STAT2 levels were examined by immunoblot-ing with specific antiserum.
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233HPIV2 V PROTEIN TARGETS STAT2stimulation that is induced approximately 20- to 25-fold
after a 6-h treatment with IFNa (Fig. 3). When either
PIV2 V protein or SV5 V protein was cotransfected with
he ISRE reporter gene, no IFN inducible activity was
bserved. These results indicate that both of the
aramyxovirus V proteins can antagonize ISRE-depen-
ent transcriptional activation by targeting different com-
onents of the ISGF3 complex.
ffect of V protein on STAT2 mRNA levels
To determine the mechanisms responsible for the V-
rotein-dependent loss of STAT2 protein accumulation
nd ISGF3 activity, STAT2 mRNA abundance was exam-
ned as a possible point of interference by HPIV2 V (Fig.
). To examine the STAT2 mRNA accumulation level, cells
ere transfected with pRcCMV vector or pRcCMV HPIV2
. Immediately following transfection (time 0) and at 12 h
osttransfection (hpt), plates were harvested for RNA
xtraction, and at 12 hpt, the growth medium on remain-
ng plates was replaced. Subsequent samples were har-
ested at 24 and 36 hpt. Total RNA was extracted and
ubjected to reverse-transcription and PCR (RT-PCR)
ith STAT2-specific primers or control primers specific
or the cellular enzyme glyceraldehyde-3-phosphate de-
ydrogenase (GAPDH) in the presence of radiolabeled
eoxynucleoside triphosphate. No products were de-
ected in control reactions carried out in the absence of
everse transcription (not shown). Only minor variations
n the level of STAT2 mRNA were observed between
ndividual plates of transfected cells. No significant dif-
erences in either STAT2 or GAPDH mRNA expression
FIG. 3. Inhibition of ISGF3-dependent transcription by expression of H
and either empty vector or paramyxovirus V protein expression vectors
subjected to luciferase assays. Results shown are normalized to cotran
standard deviation indicated.ere observed specifically in response to HPIV2 V pro-ein expression. The level of cotransfected GFP mRNA
as quantitated similarly and the data indicate that sim-
lar transfection efficiencies were obtained between in-
ividual transfected plates in a single experiment (Fig.
B). This result suggests that the loss of STAT2 protein
annot be attributed to HPIV2 V protein effects on STAT2
RNA steady-state levels.
ffect of V protein on STAT2 is posttranslational
To measure the rate of STAT2 degradation in the pres-
nce and absence of V protein, and to test directly the
ontributions of newly synthesized STAT2 to the steady-
tate pool, a time course experiment was carried out.
ecause endogenous STAT2 protein is very stable with a
ong half life (Lee et al., 1997), a time course protocol in-
olving cycloheximide (CHX) treatment was used in lieu
f inefficient metabolic labeling, based on protocols used
or examination of p53 degradation by human papilloma-
irus proteins (Talis et al., 1998). Cells were transfected
with pRcCMV vector or pRcCMV HPIV2 V, medium was
changed after 16 h, and CHX was added to half of the
plates at 24 hpt. Duplicate plates were harvested at 48,
72, and 96 hpt and cell extracts were subjected to STAT2-
specific immunoblotting. An example of representative
data from several experiments is shown in Figs. 5A and
5B. The STAT2 protein level was constant in the absence
of V protein expression, but CHX treatment resulted in a
small decrease in steady-state levels (;20–30% lost by
48 hpt), indicating a low level of STAT2 recycling in the
cells. Expression of HPIV2 V protein caused a dramatic
reduction of STAT2 after 24 h (;80% loss), after which the
protein. 293T cells were transfected with ISRE-luciferase reporter gene
cated. Following IFN stimulation for 6 h, cells were lysed at 48 hpt and
LacZ and represent average values from a triplicate experiment, withPIV2 V
as indi
sfectedSTAT2 level remained low but fairly constant, approxi-
234 PARISIEN ET AL.mately 20–40% of control levels. Addition of CHX re-
vealed a rapid loss of STAT2 to near completion by 48
hpt. Treatment of cells with IFN did not alter the V protein
effect on STAT2 and neither STAT1 nor STAT3 levels were
altered (not shown). This result indicates that steady-
state STAT2 levels are the result of high stability of the
bulk of STAT2 with approximately 20–30% of the total
protein arising due to new protein synthesis. Expression
of HPIV2 V protein results in destabilization of the pre-
existing protein but has little effect on new STAT2 protein
synthesis. These findings indicate that a primary action
of HPIV2 V against STAT2 is posttranslational degrada-
tion.
Effect of proteasome inhibitors on HPIV2 V-mediated
degradation
The results indicate that the effects of HPIV2 V protein
on STAT2 were posttranslational. As SV5-mediated
STAT1 degradation was blocked by proteasome inhibi-
tion in previously published experiments (Didcock et al.,
1999), it seemed probable that the mechanism of STAT2
degradation by HPIV2 might also involve the ubiquitin–
proteasome pathway. To test this possibility, a protea-
some inhibitor was used to treat transfected cells to
determine the effect on HPIV2 V protein-mediated STAT2
FIG. 4. Analysis of STAT2 mRNA levels upon V protein expression. A
vector or pRcCMV HPIV2 V as indicated. Each lane represents RNA
numbers indicate time (hpt) when RNA was isolated. B. Quantitation a
level of STAT2 normalized to the GAPDH control. The right graph showdegradation (Fig. 5C). When cells expressing HPIV2 Vprotein were treated with the proteasome inhibitor
MG132, little difference was observed in the STAT2
steady-state level at 72 h posttransfection. However, con-
current inhibition of new protein synthesis with CHX
treatment revealed that proteasome inhibition partially
preserved STAT2 protein from the V-protein-mediated
degradation. This result indicates only a minor role for
proteasome-mediated degradation in the actions of the
HPIV2 V protein against STAT2 and suggests that addi-
tional cellular mechanisms might also contribute to the V
protein’s activity.
DISCUSSION
The anti-viral state induced by IFN is a strong selective
pressure for virus growth and replication. To evade the
cellular IFN anti-viral effects, diverse virus types have
created equally diverse strategies for bypassing this
innate immune response. The paramyxoviruses SV5 and
Sendai virus have been recently shown to cause a loss
of cellular STAT protein accumulation, but by different
mechanisms involving transcriptional inhibition cata-
lyzed by Sendai virus C proteins (Garcin et al., 1999,
2000) or posttranslational proteasomal degradation cat-
alyzed by SV5 V protein (Didcock et al., 1999). Our finding
that infection of cells with HPIV2 leads to a loss of STAT2
R was carried out using total RNA from cells transfected with empty
d from an individual transfected 60-mm plate. U, untransfected cells;
alization of (A) by phosphorimage analysis. The left graph shows the
alized levels of cotransfected GFP mRNA.. RT-PC
isolate
nd norm
s normsteady-state protein accumulation is in general agree-
f
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235HPIV2 V PROTEIN TARGETS STAT2ment with a previous report (Young et al., 2000). Here, we
have analyzed the mechanism underlying HPIV2-medi-
ated STAT2 inhibition by demonstrating that: (1) the
HPIV2 V protein expressed in the absence of other viral
proteins can target STAT2, (2) this loss of STAT2 induced
by HPIV2 V protein expression results in defective IFN
signaling to ISRE-containing promoter elements, (3) this
loss of STAT2 is the result of V-protein-induced protein
degradation, and (4) it is not the result of general tran-
scriptional defects.
The finding of V-protein-mediated STAT2 protein deg-
FIG. 5. Posttranslational degradation of STAT2 is induced by HPIV
cycloheximide (CHX, 10 mg/ml) as indicated at 24 h posttransfection (h
or total STAT2 content by immunoblot. B. Immunoblotting results show
TAT2 in vector-transfected, CHX-untreated control lanes, and plotted.
HX-treated; filled triangles, HPIV2 V expression, CHX-untreated; open
n V-dependent STAT2 degradation. Cells were transfected with HPIV2
HX. At 64 h posttransfection, 40 mM MG132 was added and extracts
protein from a control cotransfected GFP expression vector.radation is directly analogous to SV5 degradation ofSTAT1 (Didcock et al., 1999). We hypothesize that these
two closely related viral proteins catalyze a similar reac-
tion with different substrate specificity, possibly through
interaction with and subversion of normal cellular pro-
teolytic mechanisms. Proteins from other viruses are
known that catalyze the proteolytic destruction of cellular
targets by commandeering the cell’s own degradation
machinery. The two best characterized examples are
from the study of human papilloma virus and human
immunodeficiency virus and both appropriate the ubiq-
uitin–proteasome system. The viral proteins physically
tein expression. (A and B) Cells were transfected and treated with
Cell extracts were prepared at the indicated time points and analyzed
) were quantitated by laser densitometry, normalized to the signal for
iamonds, vector control, CHX-untreated; filled squares, vector control,
, HPIV2 V expression, CHX-treated. C. Effects of proteasome inhibitor
ession plasmid and incubated at 24 h posttransfection with or without
prepared 8 h later. (Bottom) The effect of drug treatment on levels of2-V pro
pt). A.
n in (A
Filled d
circles
V expr
wereinteract with the E3 ubiquitin protein ligase enzymes by
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236 PARISIEN ET AL.forming a protein complex to bring novel targets to the
proteasome. Degradation of the tumor suppressor p53
by the oncogenic HPV 16 and 18 E6 protein was the first
example of such a mechanism (reviewed in Mantovani
and Banks, 1999; Munger et al., 1992). E6 functions by
ijacking the cellular ubiquitin-dependent proteolytic ma-
hinery to induce p53 degradation. The viral E6 protein
nteracts directly with a cellular E3 enzyme, E6AP, caus-
ng novel recognition of p53 as a proteasome substrate.
ore recently, the HIV-1 Vpu integral membrane protein
as demonstrated to catalyze the destruction of its own
eceptor, CD4, through interaction with a different E3
nzyme, bTrCP (Margottin et al., 1998). While there is no
amino acid sequence homology between the paramyxo-
virus V proteins and either the HPV-16 E6 or the HIV-1
Vpu, it is tempting to speculate that a similar mechanism
has evolved to allow the paramyxovirus V proteins to
mediate destruction of cellular STAT proteins that are
otherwise long-lived and regulated by phosphorylation
rather than transcriptional induction. Our results with
chemical inhibition, however, suggest only a partial role
for the proteasome per se in this reaction, leaving open
the possibility for alternative mechanisms of V protein
action. Future studies will be required to elucidate more
precisely the mechanisms underlying HPIV2 V protein
actions on STAT2 both in transfected cells and in the
context of HPIV2 infections.
While the action of HPIV2 V protein appears to be
similar to that of SV5 V, it differs from the IFN antagoniz-
ing effects of another paramyxovirus, Sendai virus. Ex-
pression of Sendai virus C proteins has been reported to
cause a loss of STAT protein inducibility at the transcrip-
tional level (Garcin et al., 1999, 2000), but HPIV2 V protein
apparently decreases the preexisting pool of STAT2 with-
out altering the replacement of STAT2 by new protein
synthesis. It is interesting to note that infection of cells
with HPIV1 or HPIV3, which do not degrade STAT2, ac-
tually causes somewhat increased levels of STAT2 (see
Fig. 1). It is possible that in addition to V protein actions
against STAT2, HPIV2 infection also constraints host pro-
tein synthesis.
Many other viruses have evolved strategies to combat
the IFN system, but other virus-induced mechanisms that
cause proteolytic degradation of STATs are not known.
Only one other viral protein was reported to similarly
induce the loss of a STAT protein (Leonard and Sen,
1996). In this report, it was shown that chronic adenovi-
rus E1A expression in Hela-derived cell lines corre-
sponds with a decreased level of both STAT1 and IRF9/
p48/ISGF3g (two ISGF3 components). The mechanisms
for either the STAT1 or the IRF9/p48/ISGF3g loss remain
ncharacterized, but the results with STAT1 were later
ound to differ between cell lines tested (Leonard and
en, 1997). The loss of IRF9/p48/ISGF3g, however, was
more universal and E1A-expressing HT1080 cells trans-
fected with IRF9/p48/ISGF3g expression vectors were wescued from E1A’s effects on IFN signaling. Other in-
estigations suggest that E1A blocks IFN signaling by
ompeting with STAT1 for limited basal transcription reg-
latory machinery, specifically the histone acetyl trans-
erase, CBP/p300 (Bhattacharya et al., 1996; Look et al.,
1998; Zhang et al., 1996).
The effects of paramyxovirus-induced destruction of
STAT proteins to evade IFN signaling are expected to
influence not only innate cellular antiviral response, but
also possibly the adaptive anti-viral immune responses.
STAT1 is shared by both type I and type II (IFNg) IFN
signaling pathways (Horvath, 2000; Horvath and Darnell,
1997) and is also activated downstream of many other
receptor and nonreceptor tyrosine kinases, serves as an
accessory to several cytokine pathways, and functions in
the modulation of cell death signals from apoptotic cy-
tokine receptors (Kumar et al., 1997; Wang et al., 2000).
Because of the more diverse activities of STAT1, the SV5
V protein is expected to have additional and possibly
more severe cellular outcomes because its loss could
influence additional cytokine signaling pathways in ad-
dition to type I IFN. By a similar argument, loss of STAT2
due to HPIV2 V protein expression is expected to result
in a more specific loss of type I IFN signaling at the
cellular level. Because murine and human STAT2 pro-
teins are uncharacteristically divergent (Park et al., 1999),
the HPIV2 V protein might be responsible for limiting the
host range of this virus to human cells (Ito et al., 1989).
The role of adaptive immune responses in HPIV2 infec-
tion represents a challenge for the future and will cer-
tainly provide insight into the biology of this human
pathogen.
MATERIALS AND METHODS
Cell culture and virus infection
Human 293T, 2fTGH, and monkey CV1 cells were
maintained in Dulbecco’s modified Eagle’s medium
(Gibco-BRL) and supplemented with 10% Cosmic calf
serum (Hyclone). For protein synthesis inhibition exper-
iments, specific cell lines in 60-mm dishes were treated
with 10 mg/ml of cycloheximide (Sigma). For proteasome
nhibition, Z-LLL-CHO (MG132; Sigma) was added to the
edium to 40 mM final concentration for an 8-h exposure
period (longer exposure times are cytotoxic). Treatment
with human recombinant IFNa (1000 U/ml) was started at
2–16 h posttransfection for 6 h. Stocks of human para-
nfluenza viruses types 1, 2, and 3 were prepared and
sed as described previously (Ah-Tye et al., 1999).
lasmid DNAs, transient transfections, and reporter
ene assays
Isolation of the HPIV2 V ORF was carried out by stan-
ard PCR methods (GDP, unpublished). Briefly, mRNA
as harvested by oligo dT chromatography from CV-1
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237HPIV2 V PROTEIN TARGETS STAT2cells infected with the Greer strain of HPIV-2. The V ORF
was amplified by RT-PCR using Superscript RT and Taq
polymerase. The following primers were used:
HP2-P59,
59-GCGAATTCGTGATCAGATAACCTCCA-
CACCAGAATCATAC-39;
SACI-39 vRNA sense,
59-GCCGGTACCTTTAAGAGCTCAAT-
GATCTCCTTCACATTCTCCGC-39;
he PCR product was restricted with EcoRI and Asp718
nd cloned into the same sites of pGEM3 (Promega).
hree independent clones were sequenced and found to
atch the published Toshiba strain sequence except for
single nucleotide substitution (an A to G at base 239 on
he published Toshiba sequence (Ohgimoto et al., 1990)).
his substitution converts a threonine to an alanine at
osition 56, possibly a strain-specific allelic difference. It
ay be relevant that the alanine at position 56 actually
atches better to the SV5 V protein sequence.
The pGEM3 plasmid containing the Greer strain HPIV2
ORF was the template for a second amplification of the
ORF insert by PCR using Vent Polymerase (NEB, Bev-
rly, MA). The following primers were engineered to add
lanking NotI and ApaI restriction endonuclease recog-
ition sites to the V cDNA:
59-GGGCGGCCGCGAATTCGTGATCAGATAAC-39
59-GGGGGCCCAAGAGCTCAATGATCTCC-39.
The resulting PCR product was ligated into a NotI–
paI restricted pRcCMV vector (Invitrogen) for mamma-
ian expression and the resulting construct was verified
y restriction mapping and nucleotide sequencing.
For transient cDNA transfection, cell monolayers were
rown to 60–80% confluency in 60-mm dishes. Transfec-
ion of cells with cDNAs was carried out by standard
aPO4 transfection procedures and assayed at various
imes after transfection (Ausubel et al., 1994). Transfec-
ion of 293T cells by this method is highly efficient,
esulting in typical transfection efficiencies of 95–100%
s determined by FACS analysis of GFP-transfected cells
JFL and CMH, unpublished). Nonetheless, in all experi-
ents, cotransfected controls were included to deter-
ine the uniformity and efficiency of the transfection and
o verify that all plates in a given experiment were equally
ransfected. For cell lysate analysis, 1 mg of a control
GFP expression plasmid was included for evaluation of
ransfection efficiency by inverted fluorescence micros-
opy prior to lysis. For reporter gene assays, 1 mg of a
control CMV-LacZ plasmid was added as a control for
the transfection procedure and luciferase values were
normalized to b-gal activity. In addition, 5 mg of a reporterene containing five copies of the ISG54 ISRE elementpstream of a TATA box and firefly luciferase ORF plas-
id was included. After 16 h, transfection medium was
eplaced with fresh medium supplemented with 10%
osmic calf serum. Cells were then harvested in an
ppropriate lysis buffer and analyzed either by SDS–
olyacrylamide gel electrophoresis or by measuring lu-
iferase activity according to the manufacturer’s protocol
Promega).
xtracts, antibodies, and immunoblotting
Antiserum specific for STAT1 or STAT2 were obtained
rom Santa Cruz Biotechnology, antibodies specific for
FP were obtained from Clontech, and an antibody to
PIV2-infected cell extracts was obtained from Whitaker
iochemicals. Cell extracts were prepared as described
Shuai et al., 1994). Cells were washed and scraped into
ce-cold PBS and pelleted at 1500 rpm. Subsequent cell
ellets were lysed in 2 vol of whole cell extract buffer (50
M Tris, pH 8.0, 280 mM NaCl, 0.5% IGEPAL, 0.2 mM
DTA, 2 mM EGTA, 10% glycerol, 1 mM DTT) supple-
ented with a protease inhibitor cocktail (Complete,
oehringer Mannheim) for 15 min. Cellular debris was
elleted at 14,000 rpm and the supernatant was analyzed
irectly or stored at 280°C. Samples were added to
DS–gel loading buffer, boiled for 5 min, and loaded
irectly onto SDS–polyacrylamide gels (7%, 12%). Gels
ere transferred to nitrocellulose membranes and de-
ected with specific antibodies to the C-terminal portions
f STAT1 and STAT2. Protein–antibody interactions were
etected using secondary antiserum conjugated horse-
adish peroxidase and enhanced chemiluminescence
eagents (NEN Life Sciences).
nalysis of mRNA
RT-PCR reactions were carried out as described pre-
iously (Horvath et al., 1996). Total cellular RNA was
solated with Trizol reagent (Gibco-BRL) according to the
anufacturer’s instructions. First-strand cDNAs were
ynthesized from DNAse-I-treated total RNA by use of
uperScript II reverse transcriptase (Gibco-BRL) and ran-
om antisense primers according to the manufacturer’s
nstruction. Diluted cDNAs were subjected to PCR amplifi-
ations with [a-32P]dCTP and primers specific for glycer-
ldehyde-3-phosphatase dehydrogenase (59-GTGAAGG-
CGGAGTCAAC-39 and 59-TGGAATTTGCCATGGGTG-39)
GFP 59-ACGTAAACGGCCACAAGTTC-39 and 59-AAG-
TCGTGCTGCTTCATGTG-39, or STAT2 (59-GAAGATCT-
GAAACTCTCAATGAACTGG-39 and 59-GGGAATTCCC-
TAGGGAGCTCTGATGCAGG-39).
PCR-amplified products were separated on a 5% poly-
acrylamide gel, and autoradiography was performed.
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238 PARISIEN ET AL.Samples were quantitated with a Storm phosphorimage
analyzer and ImageQuant software (Molecular Dynam-
ics).
ACKNOWLEDGMENTS
We are grateful to John Rassa for his cloning of HPIV2 V cDNAs,
Natalia Poltoratskaia for technical assistance with HPIV infections,
Chris Cardozo, Sherwin Wilk, and Avrom Caplan for advice on prote-
olysis, and Biao He for helpful discussions. This work was supported in
part by the New York City Council Speaker’s Fund for Biomedical
Research: Toward the Science of Patient Care and a Mount Sinai
Dean’s Research Incentive Award (to CMH). CMH is the Ira M. Jacob-
son, M.D., Liver Scholar of the American Liver Foundation. RAL is an
Investigator of the Howard Hughes Medical Institute.
REFERENCES
Ah-Tye, C., Schwartz, S., Huberman, K., Carlin, E., and Moscona, A.
(1999). Virus–receptor interactions of human parainfluenza viruses
types 1, 2 and 3. Microb. Pathog. 27(5), 329–336.
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G.,
Smith, J. A., and Struhl, K. (1994). “Current Protocols in Molecular
Biology.” Wiley, New York.
Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff,
K., Palese, P., and Muster, T. (2000). Influenza virus NS1 protein
counteracts PKR-mediated inhibition of replication. J. Virol. 74(13),
6203–6206.
Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z.,
D’Andrea, A., and Livingston, D. M. (1996). Cooperation of Stat2 and
p300/CBP in signalling induced by interferon a. Nature 383(26),
344–347.
Darnell, J. E., Jr. (1997). STATs and gene regulation. Science 277,
1630–1635.
Didcock, L., Young, D. F., Goodbourn, S., and Randall, R. E. (1999). The
V protein of simian virus 5 inhibits interferon signalling by targeting
STAT1 for proteasome-mediated degradation. J. Virol. 73(12), 9928–
9933.
Garcin, D., Curran, J., and Kolakofsky, D. (2000). Sendai virus C proteins
must interact directly with cellular components to interfere with
interferon action. J. Virol. 74(19), 8823–8830.
arcin, D., Latorre, P., and Kolakofsky, D. (1999). Sendai virus C proteins
counteract the interferon-mediated induction of an antiviral state.
J. Virol. 73(8), 6559–6565.
oodbourn, S., Didcock, L., and Randall, R. E. (2000). Interferons: Cell
signalling, immune modulation, antiviral response and virus counter-
measures. J. Gen. Virol. 81(Pt. 10), 2341–2364.
orvath, C. M. (2000). STAT proteins and transcriptional responses to
extracellular signals. TIBS 25, 496–502.
orvath, C. M., and Darnell, J. E., Jr. (1996). The antiviral state induced
by alpha interferon and gamma interferon requires transcriptionally
active Stat1 protein. J. Virol. 70, 647–650.
orvath, C. M., and Darnell, J. E., Jr. (1997). The state of the STATs:
Recent developments in the study of signal transduction to the
nucleus. Curr. Opin. Cell Biol. 9(2), 233–239.
orvath, C. M., Stark, G. R., Kerr, I. M., and Darnell, J. E., Jr. (1996).
Interactions between STAT and non-STAT proteins in the interferon
stimulated gene factor 3 transcription complex. Mol. Cell. Biol. 16(12),
6957–6964.
saacs, A., and Lindemann, J. (1957). Virus interference. I. The inter-
feron. Proc. R. Soc. Lond. B 147, 258–267.
Ito, Y., Tsurudome, M., Bando, H., Komada, H., and Nishio, M. (1989).
Incomplete replication of human parainfluenza virus type 2 in mouse
L929 cells. Arch. Virol. 108(1–2), 137–144.itajewski, J., Schneider, R. J., Safer, B., Munemitsu, S. M., Samuel,
C. E., Thimmappaya, B., and Shenk, T. (1986). Adenovirus VAI RNA
antagonizes the antiviral action of interferon by preventing acti-
vation of the interferon-induced eIF-2 alpha kinase. Cell 45(2),
195–200.
umar, A., Commane, M., Flickinger, T. W., Horvath, C. M., and Stark,
G. R. (1997). Defective tumor necrosis factor-a induced apoptosis in
STAT1-null cells due to low constitutive levels of caspases. Science
278, 1630–1632.
Lau, J. F., and Horvath, C. M. Unpublished observations.
Lau, J. F., Parisien, J. P., and Horvath, C. M. (2000). Interferon regulatory
factor subcellular localization is determined by a bipartite nuclear
localization signal in the DNA-binding domain and interaction with
cytoplasmic retention factors. Proc. Natl. Acad. Sci. USA 97(13),
7278–7283.
Lee, C. K., Bluyssen, H. A., and Levy, D. E. (1997). Regulation of
interferon-alpha responsiveness by the duration of Janus kinase
activity. J. Biol. Chem. 272(35), 21872–21877.
Leonard, G. T., and Sen, G. C. (1996). Effects of adenovirus E1A protein
on interferon-signaling. Virology 224(1), 25–33.
Leonard, G. T., and Sen, G. C. (1997). Restoration of interferon re-
sponses of adenovirus E1A-expressing HT1080 cell lines by overex-
pression of p48 protein. J. Virol. 71(7), 5095–5101.
eung, S., Qureshi, S. A., Kerr, I. M., Darnell, J. E., Jr., and Stark, G. R.
(1995). Role of STAT2 in the interferon-a/b signaling pathway. Mol.
Cell. Biol. 15, 1312–1317.
evy, D. E., Kessler, D. S., Pine, R. I., and Darnell, J. E., Jr. (1989).
Cytoplasmic activation of ISGF3, the positive regulator of interferon-a
stimulated transcription, reconstituted in vitro. Genes Dev. 3, 1362–
1372.
Look, D. C., Roswit, W. T., Frick, A. G., Gris-Alevy, Y., Dickhaus, D. M.,
Walter, M. J., and Holtzman, M. J. (1998). Direct suppression of
Stat1 function during adenoviral infection. Immunity 9(6), 871–
880.
Mantovani, F., and Banks, L. (1999). The interaction between p53 and
papillomaviruses. Semin. Cancer Biol. 9(6), 387–395.
Margottin, F., Bour, S. P., Durand, H., Selig, L., Benichou, S., Richard, V.,
Thomas, D., Strebel, K., and Benarous, R. (1998). A novel human WD
protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to
the ER degradation pathway through an F-box motif. Mol. Cell. 1(4),
565–574.
Martinez-Moczygemba, M., Gutch, M. J., French, D. L., and Reich, N. C.
(1997). Distinct STAT structure promotes interaction of STAT2 with the
p48 subunit of the interferon-alpha-stimulated transcription factor
ISGF3. J. Biol. Chem. 272(32), 20070–20076.
Munger, K., Scheffner, M., Huibregtse, J. M., and Howley, P. M. (1992).
Interactions of HPV E6 and E7 oncoproteins with tumour suppressor
gene products. Cancer Surv. 12, 197–217.
Ohgimoto, S., Bando, H., Kawano, M., Okamoto, K., Kondo, K., Tsuru-
dome, M., Nishio, M., and Ito, Y. (1990). Sequence analysis of P gene
of human parainfluenza type 2 virus: P and cysteine-rich proteins are
translated by two mRNAs that differ by two nontemplated G residues.
Virology 177(1), 116–123.
Park, C., Lecomte, M. J., and Schindler, C. (1999). Murine Stat2 is
uncharacteristically divergent. Nucleic Acids Res. 27(21), 4191–
4199.
Qureshi, S. A., Leung, S., Kerr, I. M., Stark, G. R., and Darnell, J. E., Jr.
(1996). Function of Stat2 protein in transcriptional activation by IFN-a.
Mol. Cell. Biol. 16, 288–293.
huai, K., Horvath, C. M., Tsai-Huang, L. H., Qureshi, S., Cowburn, D.,
and Darnell, J. E., Jr. (1994). Interferon activation of the transcription
factor Stat91 involves dimerization through SH2-phosphotyrosyl pep-
tide interactions. Cell 76, 821–828.
alis, A. L., Huibregtse, J. M., and Howley, P. M. (1998). The role of E6AP
in the regulation of p53 protein levels in human papillomavirus
239HPIV2 V PROTEIN TARGETS STAT2(HPV)-positive and HPV-negative cells. J. Biol. Chem. 273(11), 6439–
6445.
Talon, J., Horvath, C. M., Polley, R., Basler, C. F., Muster, T., Palese, P.,
and Garcia-Sastre, A. (2000). Activation of interferon regulatory factor
3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74(17),
7989–7996.
Wang, Y., Wu, T. R., Cai, S., Welte, T., and Chin, Y. E. (2000). Stat1 as a
component of tumor necrosis factor alpha receptor 1-TRADD signal-
ing complex to inhibit NF-kappaB activation. Mol. Cell. Biol. 20(13),
4505–4512.Young, D. F., Didcock, L., Goodbourn, S., and Randall, R. E. (2000).
Paramyxoviridae use distinct virus-specific mechanisms to circum-
vent the interferon response. Virology 269(2), 383–390.
Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., and
Darnell, J. E., Jr. (1996). Two contact regions between Stat1 and
CBP/p300 in interferon g signaling. Proc. Natl. Acad. Sci. USA 93,
15092–15096.
Zhou, A., Paranjape, J. M., Der, S. D., Williams, B. R., and Silverman, R. H.
(1999). Interferon action in triply deficient mice reveals the existence
of alternative antiviral pathways. Virology 258(2), 435–440.
